[go: up one dir, main page]

WO2009107864A3 - Comprimé à désintégration orale - Google Patents

Comprimé à désintégration orale Download PDF

Info

Publication number
WO2009107864A3
WO2009107864A3 PCT/JP2009/054115 JP2009054115W WO2009107864A3 WO 2009107864 A3 WO2009107864 A3 WO 2009107864A3 JP 2009054115 W JP2009054115 W JP 2009054115W WO 2009107864 A3 WO2009107864 A3 WO 2009107864A3
Authority
WO
WIPO (PCT)
Prior art keywords
cilostazol
orally disintegrating
disintegrating tablet
mannitol
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2009/054115
Other languages
English (en)
Other versions
WO2009107864A2 (fr
Inventor
Hidekazu Okazaki
Naoki Kamada
Masafumi Toda
Tadashi Fukami
Haruka Koizumi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to EP09714454A priority Critical patent/EP2262487A2/fr
Priority to JP2010504975A priority patent/JP2011513194A/ja
Publication of WO2009107864A2 publication Critical patent/WO2009107864A2/fr
Publication of WO2009107864A3 publication Critical patent/WO2009107864A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un comprimé à désintégration orale comprenant du cilostazol, du mannitol, un saccharide autre que le mannitol, une substance inorganique, et un agent de désintégration, ainsi qu'un excipient organique et qu'un agent de glissement. Ce comprimé peut être pris de manière simple par de nombreux patients traités par des comprimés au cilostazol, en particulier des patients agés et des patients souffrant de dysphagie.
PCT/JP2009/054115 2008-02-29 2009-02-26 Comprimé à désintégration orale Ceased WO2009107864A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP09714454A EP2262487A2 (fr) 2008-02-29 2009-02-26 Comprimé de cilostazol à désintégration orale
JP2010504975A JP2011513194A (ja) 2008-02-29 2009-02-26 口腔内崩壊錠

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008050460 2008-02-29
JP2008-050460 2008-02-29

Publications (2)

Publication Number Publication Date
WO2009107864A2 WO2009107864A2 (fr) 2009-09-03
WO2009107864A3 true WO2009107864A3 (fr) 2009-12-03

Family

ID=40718911

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/054115 Ceased WO2009107864A2 (fr) 2008-02-29 2009-02-26 Comprimé à désintégration orale

Country Status (7)

Country Link
EP (1) EP2262487A2 (fr)
JP (1) JP2011513194A (fr)
AR (1) AR070530A1 (fr)
CL (1) CL2009000452A1 (fr)
PE (1) PE20091560A1 (fr)
TW (1) TW200936184A (fr)
WO (1) WO2009107864A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8779146B2 (en) 2010-04-28 2014-07-15 Nuformix Limited Cilostazol cocrystals and compositions
ES2422657B1 (es) * 2012-02-10 2014-06-11 Laboratorios Normon S.A. Composición farmacéutica sólida de cilostazol
US9988542B2 (en) 2012-07-20 2018-06-05 Otsuka Pharmaceutical Co., Ltd. Tablet having dry-ink film on surface thereof, and ink for inkjet printer
KR20160030093A (ko) 2013-07-19 2016-03-16 가부시키가이샤산와카가쿠켄큐쇼 구강 내 붕괴정
JP6476122B2 (ja) * 2013-09-27 2019-02-27 株式会社ダイセル 二段階の湿式造粒工程で製造される崩壊性粒子組成物及び該組成物を含む口腔内崩壊錠剤
US10231914B2 (en) * 2015-06-02 2019-03-19 Lynette Batton Effervescent tablet for elimination of red wine discoloration, offensive odour of mouth and cleaning the palate
EP3409294A1 (fr) 2017-06-01 2018-12-05 Przedsiebiorstwo Farmaceutyczne Lek-Am Sp Z O. O. Comprimés contenant du cilostazol de distribution granulométrique spécifique

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041807A2 (fr) * 1999-12-10 2001-06-14 Vivus, Inc. Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection
US20020058066A1 (en) * 2000-09-22 2002-05-16 Otsuka Pharmaceutical Co., Ltd. Cilostazol dry coated tablet
EP1523974A1 (fr) * 2003-10-15 2005-04-20 Fuji Chemical Industry Co., Ltd. Composition pour comprimés à délitement rapide dans la cavité buccale
EP1674083A1 (fr) * 2003-10-15 2006-06-28 Fuji Chemical Industry Co., Ltd. Comprime se desintegrant rapidement dans la cavite buccale

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076565A1 (fr) * 2000-04-12 2001-10-18 Banyu Pharmaceutical Co., Ltd. Compositions et preparations se desintegrant dans la cavite buccale
JP4551627B2 (ja) * 2003-02-28 2010-09-29 東和薬品株式会社 口腔内崩壊錠剤の製造方法
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
WO2007029376A1 (fr) * 2005-09-02 2007-03-15 Fuji Chemical Industry Co., Ltd. Comprimé se désintégrant rapidement dans la bouche

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001041807A2 (fr) * 1999-12-10 2001-06-14 Vivus, Inc. Administration a travers les muqueuses d'inhibiteurs de la phosphodiesterase dans le traitement de la dyserection
US20020058066A1 (en) * 2000-09-22 2002-05-16 Otsuka Pharmaceutical Co., Ltd. Cilostazol dry coated tablet
EP1523974A1 (fr) * 2003-10-15 2005-04-20 Fuji Chemical Industry Co., Ltd. Composition pour comprimés à délitement rapide dans la cavité buccale
EP1674083A1 (fr) * 2003-10-15 2006-06-28 Fuji Chemical Industry Co., Ltd. Comprime se desintegrant rapidement dans la cavite buccale

Also Published As

Publication number Publication date
AR070530A1 (es) 2010-04-14
TW200936184A (en) 2009-09-01
EP2262487A2 (fr) 2010-12-22
WO2009107864A2 (fr) 2009-09-03
JP2011513194A (ja) 2011-04-28
CL2009000452A1 (es) 2010-03-26
PE20091560A1 (es) 2009-10-30

Similar Documents

Publication Publication Date Title
WO2009117421A3 (fr) Modulateurs hétérocycliques de gpr119 pour le traitement d’une maladie
WO2009107864A3 (fr) Comprimé à désintégration orale
IL199472A0 (en) Non-effervescent, orally disintegrating solid pharmaceutical dosage forms, processes for the preparation of the same and uses thereof
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
WO2012088266A3 (fr) Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
WO2010088518A3 (fr) Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2010129816A3 (fr) Composés hétérocycliques et leurs utilisations
WO2010062377A3 (fr) Procédés et compositions pour la détection et le traitement de l’éclampsie
CL2014003171A1 (es) Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica.
WO2010048149A3 (fr) Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
IL225198A (en) Aminotetrahydropyrenic Compounds, Pharmaceutical Preparations Containing Them and Their Use in the Treatment of Diabetes
WO2010146179A3 (fr) Composition pharmaceutique solide comprenant du rivaroxaban
WO2011106322A3 (fr) Biomarqueurs pour accident ischémique cérébral aigu
CL2007001993A1 (es) Compuestos derivados de pirimidilciclopentanos hidroxilados y metoxilados; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una enfermedad inflamatoria, hiperproliferante, cardiovascular, neurodegenerat
WO2011099832A3 (fr) Nouveau composé de benzimidazole, son procédé de préparation et composition pharmaceutique le contenant
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
EA201071378A1 (ru) Дронедарон для предотвращения постоянной фибрилляции предсердий
IN2012DN02471A (fr)
WO2010060624A3 (fr) Traitement à sec et nouvelles formes de lacosamide
WO2009115084A3 (fr) Nouveaux dérivés de pyrrolopyrimidine et leurs utilisations
WO2011048563A3 (fr) Comprimés de bétahistine fondant dans la bouche
CL2007003190A1 (es) Compuestos derivados de arilsulfonil-pirrolidinas; procedimiento de obtencion; composicion farmaceutica; y uso en la prevencion o tratamiento de enfermedades tales como psicosis, depresion, alzheimer, entre otras.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09714454

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009714454

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010504975

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE